Loading...
Market
Will ARS Pharmaceuticals announce a significant partnership for Neffy distribution by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
ARS Pharmaceuticals press releases and major news outlets
Story
FDA Approves Neffy, First Needle-Free Epinephrine Treatment for Anaphylaxis
Aug 9, 2024, 04:52 PM
The U.S. Food and Drug Administration (FDA) has approved a new epinephrine nasal spray, neffy, developed by ARS Pharmaceuticals, as the first needle-free treatment for severe allergic reactions, including anaphylaxis. This approval, announced on Friday, marks a significant advancement in the treatment of allergic emergencies, offering an alternative to traditional epinephrine auto-injectors like the EpiPen. The nasal spray is approved for use in adults and pediatric patients who weigh at least 66 pounds. The FDA's decision is seen as a major step in improving accessibility and ease of use for individuals at risk of life-threatening allergic reactions.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
